Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20652960 | 0.92 | TP53 (0.42) | MEN1KMT2APOLBUSP1KDM4E | |
| SCHEMBL20653050 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2APOLBUSP1KDM4E | |
| SCHEMBL20652772 | 0.91 | ALDH1A1 (0.41) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL20652967 | 0.91 | ALDH1A1 (0.45) | MEN1KMT2APOLBUSP1KDM4E | |
| SCHEMBL20653129 | 0.89 | ALDH1A1 (0.40) | MDM2MEN1KMT2AUSP1KDM4E | |
| SCHEMBL20652748 | 0.88 | ALDH1A1 (0.40) | MDM2MEN1KMT2AUSP1KDM4E | |
| SCHEMBL20656166 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2APOLBUSP1KDM4E | |
| SCHEMBL24095606 | 0.84 | MDM2 (0.43) | MDM2USP1GPBAR1P2RX3 | |
| SCHEMBL20656165 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2APOLBUSP1KDM4E | |
| SCHEMBL20652966 | 0.82 | MDM2 (0.43) | MDM2USP1GPBAR1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-10329292-B2 | Substituted xanthine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329292-B2 | Substituted xanthine derivatives | TRPC5, TRPV1, TRPC4 | MDM2 4354/4885MEN1 4272/4885KMT2A 4180/4885 |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPV1 | MDM2 4635/4885MEN1 4447/4885KMT2A 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.